Point72 Asset Management’s ProQR Therapeutics PRQR Stock Holding History

Point72 Asset Management’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.22M	Sell	755,842 -57,808	-7%	-$94.8K	﹤0.01%	2627
2025 Q4	$1.64M	Buy	813,650 +63,650	+8%	+$149K	﹤0.01%	2593
2025 Q3	$1.6M	Hold	750,000	–	–	﹤0.01%	1536
2025 Q2	$1.53M	Hold	750,000	–	–	﹤0.01%	1412
2025 Q1	$998K	Sell	750,000 -741,275	-50%	-$1.58M	﹤0.01%	1448
2024 Q4	$3.95M	Buy	+1,491,275	New	+$4.74M	0.01%	1026
2022 Q1	–	Sell	-461,000	Closed	-$3.69M	–	1341
2021 Q4	$3.69M	Buy	461,000 +3,100	+0.7%	+$23.6K	0.01%	733
2021 Q3	$3.83M	Buy	+457,900	New	+$2.99M	0.02%	709
2021 Q2	–	Sell	-1,521,800	Closed	-$10.1M	–	1129
2021 Q1	$10.1M	Buy	+1,521,800	New	+$7.78M	0.05%	424
2015 Q3	–	Sell	-100	Closed	-$2K	–	879
2015 Q2	$2K	Sell	100 -2,400	-96%	-$45.2K	﹤0.01%	701
2015 Q1	$55K	Buy	+2,500	New	+$51.6K	﹤0.01%	665

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Point72 Asset Management's PRQR Position: Q1 2026 in Review

Point72 Asset Management reduced its ProQR Therapeutics (PRQR) stake by 7.1% in Q1 2026, selling an estimated $94.8K and leaving 755,842 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #2627.

Point72 Asset Management first reported a position in PRQR in Q1 2015 and has held it in 11 quarters since. The position peaked at $10.1M in Q1 2021. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

Point72 Asset Management held 755,842 shares of ProQR Therapeutics worth $1.22M as of Q1 2026.
Point72 Asset Management sold 57,808 ProQR Therapeutics shares in Q1 2026, an estimated $94.8K.
ProQR Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2627 holding.
Point72 Asset Management first reported a position in ProQR Therapeutics in Q1 2015 and has held it in 11 quarters since.
Point72 Asset Management's ProQR Therapeutics position peaked at $10.1M in Q1 2021.
69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.